Dataset Information

The Characteristics of Treated Pulmonary Arterial Hypertension Patients in Ontario.

ABSTRACT: Background. There are no Canadian prevalence studies on pulmonary arterial hypertension (PAH) to date. We described the characteristics of treated PAH patients and the healthcare utilization and costs associated with PAH in a population of public drug plan beneficiaries in Ontario, Canada. Methods. A retrospective cross-sectional analysis was conducted between April 2010 and March 2011 to identify treated PAH patients using population-based health administrative databases. We investigated demographic and clinical characteristics of treated PAH patients and conducted a cohort study to determine treatment patterns, healthcare utilization, and associated costs, over a one-year follow-up period (March 2012). Results. We identified 326 treated PAH cases in Ontario's publicly funded drug plan. Overall mean age was 59.4 years (±20.3 years) and over 77% of cases were women (n = 251). Combination therapy was used to treat 22.9% (n = 69) of cases, costing an average of $4,569 (SD $1,544) per month. Median monthly healthcare costs were $264 (IQR $96-$747) for those who survived and $2,021 (IQR $993-$6,399) for those who died over a one-year period, respectively (p < 0.01). Conclusions. PAH care in Ontario is complex and has high healthcare costs. This data may help guide towards improved patient management.

SUBMITTER: Vaid HM

PROVIDER: S-EPMC4904539 | biostudies-literature | 2016

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

The Characteristics of Treated Pulmonary Arterial Hypertension Patients in Ontario.

Vaid Haris M HM Camacho Ximena X Granton John T JT Mamdani Muhammad M MM Yao Zhan Z Singh Samantha S Juurlink David N DN Gomes Tara T

Canadian respiratory journal 20160411

Background. There are no Canadian prevalence studies on pulmonary arterial hypertension (PAH) to date. We described the characteristics of treated PAH patients and the healthcare utilization and costs associated with PAH in a population of public drug plan beneficiaries in Ontario, Canada. Methods. A retrospective cross-sectional analysis was conducted between April 2010 and March 2011 to identify treated PAH patients using population-based health administrative databases. We investigated demogr ...[more]

PMID: 27445555

Similar Datasets

Project description:Peking Union Medical College Hospital (PUMCH) has started a single-center right heart catheterization (RHC)-based pulmonary arterial hypertension (PAH) study in systemic lupus erythematosus (SLE) since 2006. The baseline characteristics of these patients were described and the risk factor for PAH in lupus was identified.The demographic, clinical, laboratory, and treatment characteristics of SLE patients with PAH when they were registered were collected as the baseline data. A case-control study was conducted by taking the admitted SLE-non-PAH patients adjusted for age and gender in a 4:1 ratio during the same period as the controls. The associated variables were examined by binary multivariate logistic regression analysis to identify possible risk factors. A total of 111 RHC-confirmed SLE-PAH patients were enrolled, with the onset age of 34.6?±?8.6 years old and the average SLE duration of 5 years. RHC revealed mPAP as 46.4?±?11.4 mm Hg, CI as 2.7?±?0.8?L/min?×?m, and PVR as 10.5?±?4.8 WU. 46% of patients were WHO Fc I-II. All patients were treated with immunosuppressive agents and 65% patients had PAH-targeted therapy. The case-control study had confirmed 2 independent risk factors previously published: pericardial effusion (OR?=?21.290, P?<?0.001) and anti-RNP antibody (OR?=?12.399, P?<?0.001). Meanwhile, 6 independent variables were discovered: baseline SLE duration (OR?=?1.118, P?=?0.007), interstitial lung disease (OR?=?17.027, P?<?0.001=, without acute rash (OR?=?3.258, P?=?0.019), anti-SSA antibody (OR?=?4.836, P?=?0.004), SLEDAI?9 (OR?=?26.426, P?<?0.001), ESR?20?mm/h (OR?=?12.068, P?<?0.001), and uric acid?>?357??mol/L (OR?=?9.666, P?<?0.001) to be associated with PAH in SLE patients.The PUMCH study has shown that SLE patients complicated with PAH are usually earlier diagnosed and have less disease severity than patients without PAH. The immunosuppressive therapy rate and the PAH target therapy rate were high, which is consistent with reports from Western countries. This study has confirmed that pericardial effusion and positive anti-RNP antibody are risk factors for SLE-associated PAH. Long SLE disease duration, the presence of interstitial lung disease, without acute skin rash, positive anti-SSA antibody, low SLEDAI and ESR, and high uric acid levels are also associated with PAH in SLE patients.

Dataset Information

The Characteristics of Treated Pulmonary Arterial Hypertension Patients in Ontario.

Publications

The Characteristics of Treated Pulmonary Arterial Hypertension Patients in Ontario.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure